In today's ACT Brief, we examine quantified reductions in trial visits through selective safety data collection, why protocol ...

Protocol design does not struggle in the protocol. It struggles in the transition to trial, when assumptions embedded in the ...

FDA proof-of-concept trials with AstraZeneca and Amgen validate continuous data transmission and signal detection, setting ...

In today's ACT Brief, we examine what the FDA's real-time oversight initiative demands of sponsors, why clinical data ...

In today's ACT Brief, we recap key themes from DIA 2026 on operational priorities and regulatory shifts, examine ...

NEJM editors cited post–database lock readjudication after trial unblinding, undisclosed to two academic authors, as inconsistent with proper research conduct and sufficient to retract the publication ...

In today's ACT Brief, we examine regulatory uncertainty and 2026 breakthroughs shaping clinical research, reimagining CRO ...

Microsoft 365 Copilot deployment aims to automate high-volume, repeatable work, freeing clinical operations staff for ...

This article argues that improving financial outcomes—including more reliable revenue recognition—requires revisiting the ...

In today's ACT Brief, we examine HHS coordinated effort to restore US clinical research leadership, two decades of rising ...

In this video interview following the 2026 DIA Global Annual Meeting, Jonathan Andrus, co-CEO of CRIO, explains why ...

In today's ACT Brief, we examine HHS coordinated effort to restore US clinical research leadership, two decades of rising protocol complexity, and data architecture frameworks for AI sustainability. A ...